503 related articles for article (PubMed ID: 31222577)
1. Recognition of early and late stages of bladder cancer using metabolites and machine learning.
Kouznetsova VL; Kim E; Romm EL; Zhu A; Tsigelny IF
Metabolomics; 2019 Jun; 15(7):94. PubMed ID: 31222577
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
3. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.
Tripathi P; Somashekar BS; Ponnusamy M; Gursky A; Dailey S; Kunju P; Lee CT; Chinnaiyan AM; Rajendiran TM; Ramamoorthy A
J Proteome Res; 2013 Jul; 12(7):3519-28. PubMed ID: 23731241
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls.
Kim WT; Yun SJ; Yan C; Jeong P; Kim YH; Lee IS; Kang HW; Park S; Moon SK; Choi YH; Choi YD; Kim IY; Kim J; Kim WJ
Yonsei Med J; 2016 Jul; 57(4):865-71. PubMed ID: 27189278
[TBL] [Abstract][Full Text] [Related]
5. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.
McNeil BK; Sorbellini M; Grubb RL; Apolo A; Cecchi F; Athauda G; Cohen B; Giubellino A; Simpson H; Agarwal PK; Coleman J; Getzenberg RH; Netto GJ; Shih J; Linehan WM; Pinto PA; Bottaro DP
J Transl Med; 2014 Oct; 12():199. PubMed ID: 25335552
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of machine learning-based pathomics signature for diagnosis and survival prediction of bladder cancer.
Chen S; Jiang L; Zheng X; Shao J; Wang T; Zhang E; Gao F; Wang X; Zheng J
Cancer Sci; 2021 Jul; 112(7):2905-2914. PubMed ID: 33931925
[TBL] [Abstract][Full Text] [Related]
7. Diagnostics of ovarian cancer via metabolite analysis and machine learning.
Yao JZ; Tsigelny IF; Kesari S; Kouznetsova VL
Integr Biol (Camb); 2023 Apr; 15():. PubMed ID: 37032481
[TBL] [Abstract][Full Text] [Related]
8. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
Yang C; Sun X; Wang H; Lu T; Wu K; Guan Y; Tang J; Liang J; Sun R; Guo Z; Zheng S; Wu X; Jiang H; Jiang X; Zhong B; Niu X; Sun S; Wang X; Chen M; Fu G
Int J Mol Med; 2019 Nov; 44(5):1952-1962. PubMed ID: 31545404
[TBL] [Abstract][Full Text] [Related]
10. Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response.
Xu W; Anwaier A; Ma C; Liu W; Tian X; Palihati M; Hu X; Qu Y; Zhang H; Ye D
Ann Med; 2021 Dec; 53(1):596-610. PubMed ID: 33830879
[TBL] [Abstract][Full Text] [Related]
11. Urinary bladder cancer staging in CT urography using machine learning.
Garapati SS; Hadjiiski L; Cha KH; Chan HP; Caoili EM; Cohan RH; Weizer A; Alva A; Paramagul C; Wei J; Zhou C
Med Phys; 2017 Nov; 44(11):5814-5823. PubMed ID: 28786480
[TBL] [Abstract][Full Text] [Related]
12. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
[TBL] [Abstract][Full Text] [Related]
13. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
[TBL] [Abstract][Full Text] [Related]
15. Raman chemometric urinalysis (Rametrix) as a screen for bladder cancer.
Huttanus HM; Vu T; Guruli G; Tracey A; Carswell W; Said N; Du P; Parkinson BG; Orlando G; Robertson JL; Senger RS
PLoS One; 2020; 15(8):e0237070. PubMed ID: 32822394
[TBL] [Abstract][Full Text] [Related]
16. Discovering biomarkers in bladder cancer by metabolomics.
Zhang WT; Zhang ZW; Guo YD; Wang LS; Mao SY; Zhang JF; Liu MN; Yao XD
Biomark Med; 2018 Dec; 12(12):1347-1359. PubMed ID: 30507300
[TBL] [Abstract][Full Text] [Related]
17. Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach.
Jacyna J; Wawrzyniak R; Balayssac S; Gilard V; Malet-Martino M; Sawicka A; Kordalewska M; Nowicki Ł; Kurek E; Bulska E; Patejko M; Markuszewski M; Gutknecht P; Matuszewski M; Siebert J; Kaliszan R; Markuszewski MJ
Talanta; 2019 Sep; 202():572-579. PubMed ID: 31171223
[TBL] [Abstract][Full Text] [Related]
18. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
Wang R; Kang H; Zhang X; Nie Q; Wang H; Wang C; Zhou S
BMC Cancer; 2022 Feb; 22(1):214. PubMed ID: 35220945
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Finding distinctions between oral cancer and periodontitis using saliva metabolites and machine learning.
Kouznetsova VL; Li J; Romm E; Tsigelny IF
Oral Dis; 2021 Apr; 27(3):484-493. PubMed ID: 32762095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
